GPT and metabolic dysfunction-associated steatotic liver disease: More importantly, CpC-treated HFD mice showed higher serum ALT and AST levels in the presence of miR-137-3p agomir, indicating that miR-137-3p agomir-mediated hepatoprotective effects against NAFLD were blunted by AMPKα inhibition (Figure 5(j)).